Access beLAB1407 and beLAB2122 world leading drug discovery platforms

Access beLAB1407 and beLAB2122 world leading drug discovery platforms

To help our academic partners realise their drug discovery ideas, beLAB1407 and beLAB2122 offer preferred access to Evotec´s world leading drug discovery platforms and expertise.

From HTS to preclinical drug development, from small molecules to gene therapy, we provide you with all the necessary expertise and experimentation to develop your ideas to the clinic.

Starting in March 2023, in a series of tailored presentations, beLAB2122 and beLAB1407 would like to invite all our academic partners to join a special series of 1 hour webinars highlighting some of the key technologies that are available to you via the funding scheme.

From Evotec specialists you will be guided through diverse topics with the opportunity to explore how beLAB212 and beLAB1407 can support your drug discovery needs.

Over the course of 2023, the following topics will be presented by Evotec´s experts:

•  Hit identification capabilities including HTS and virtual screening – 22nd March 2023 2 pm CET / 1 pm GMT 
•  Generation and optimisation of human antibodies
•  Medicinal chemistry optimisation of early-stage hits
•  RNA and DNA targeting
•  Drugging the undruggable, anti-sense oligonucleotides and protein degraders

 This is a great opportunity to hear how beLAB1407 and beLAB2122 can support you in your ambitions to develop tomorrow´s drugs. We look forward to welcoming you!

For questions please contact Mark Slack [email protected] & Friedrich Reinhard [email protected].